Sign In to View Organizational & Contract Pricing.
Select a Size
About This Item
Empirical Formula (Hill Notation):
C16H15N3OS
CAS Number:
Molecular Weight:
297.37
UNSPSC Code:
51111800
NACRES:
NA.77
MDL number:
Product Name
Tanaproget, ≥98% (HPLC)
SMILES string
S=C1Nc2c(cc(cc2)c3[n](c(cc3)C#N)C)C(O1)(C)C
InChI
1S/C16H15N3OS/c1-16(2)12-8-10(4-6-13(12)18-15(21)20-16)14-7-5-11(9-17)19(14)3/h4-8H,1-3H3,(H,18,21)
InChI key
PYVFWTPEBMRKSR-UHFFFAOYSA-N
assay
≥98% (HPLC)
form
powder
color
white to beige
solubility
DMSO: 2 mg/mL, clear
storage temp.
−20°C
Quality Level
Related Categories
Biochem/physiol Actions
Non-steroidal progesterone receptor agonist
Tanaproget is a high affinity, high efficacy and selective orally available non-steroidal progesterone receptor agonist.
signalword
Danger
hcodes
Hazard Classifications
Repr. 1B
Storage Class
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
Regulatory Information
新产品
This item has
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Richard C Winneker et al.
Steroids, 73(7), 689-701 (2008-05-13)
Progesterone receptor (PR) modulators have evolved both structurally and mechanistically over the past half-century. Classical steroidal PR agonists continue to play an important role in women's health such as in oral contraception and post-menopausal hormone therapy whereas steroid-based PR antagonists
Jody L Bapst et al.
Contraception, 74(5), 414-418 (2006-10-19)
This study aimed to evaluate the pharmacokinetics, pharmacodynamics and safety of the nonsteroidal progesterone receptor agonist, tanaproget. A randomized, double-blind, placebo-controlled, sequential-group study of ascending single doses of tanaproget was conducted in healthy, 25- to 45-year-old women on cycle days
Louis Allott et al.
EJNMMI radiopharmacy and chemistry, 4(1), 1-1 (2019-10-30)
The histological evaluation of estrogen receptor (ER) and progesterone receptor (PR) expression in breast cancer lesions from biopsy tissue can stratify patients to receive endocrine therapy. Furthermore, PR expression can predict response to selective estrogen receptor modulators (SERMs). Current immunohistochemical
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service